EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY 4.0

A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer

Andrew Hudson, Anuradha Jayaram, Benjamin Garmezy, Nicholas A Zorko, Kevin K Zarrabi, Ligi Mathews, Brent Rupnow, Mengjie Li, Debopriya Ghosh, Karen Urtishak, Peter Francis, Sherry C Wang und 2 weitere

Cancer Chemotherapy and Pharmacology · 2026

DOI: 10.1007/s00280-025-04846-w ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Andrew Hudson und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Christie NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antibodies, Bispecific, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Prostate-specific membrane antigen (PSMA) has been identified as a therapeutic target for metastatic castration-resistant prostate cancer (mCRPC). The recent success of radioligands targeting PSMA spurred development of new PSMA-targeting agents including immunotherapy. JNJ-80038114 is a bispecific antibody that binds PSMA on tumor cells and CD3 on T cells to induce anti-tumor activity.

Methods

This was a phase 1, open-label, multicenter study of JNJ-80038114 in participants with mCRPC and ≥ 1 prior systemic therapy. JNJ-80038114 was administered subcutaneously every 3 weeks (Q3W), starting at 0.1 mg. The primary endpoint was safety. Secondary endpoints included pharmacokinetics (PK), immunogenicity, and prostate-specific antigen (PSA).

Results

At final analysis, 39 participants received 0.1–180 mg JNJ-80038114 across 11 dose-escalation cohorts for a median of 9.3 weeks (range, 0.1–31.1). The most common treatment-related adverse events (TRAEs; ≥20%) included cytokine release syndrome (CRS, 51.3%, all Grade 1–2), injection-site reactions (46.2%), and fatigue (30.8%). Related Grade ≥ 3 TRAEs occurred in 51.3% of participants; dose-limiting toxicities occurred in 3 (7.7%). Four participants (10.3%) developed clinically significant neuropathies. In 37 PK-evaluable participants, mean exposure (C max , AUC) increased with increasing doses. Anti-drug antibodies (ADA) were reported in 56.8% (21/37) participants. One participant had confirmed PSA decrease ≥ 50%. Three participants had radiological responses in the context of rapidly rising PSA. Following a review of data, the study was terminated.

Conclusions

This first-in-human study of JNJ-80038114 was discontinued early due to its lack of preliminary clinical activity, neurologic toxicities, high rates of CRS, and the development of ADAs impacting PK. Clinicaltrial.Gov information NCT05441501, Registered July 1, 2022.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAntibodies, BispecificGlutamate Carboxypeptidase IIHumansMaleAgedMiddle AgedDose-Response Relationship, DrugAged, 80 and overProstate-Specific AntigenAntigens, SurfaceCD3 Complex

Stichwörter der Autor:innen

Bispecific antibodyFirst-in-humanJNJ-80038114Metastatic castration-resistant prostate cancerPSMA

Substanzen

Antibodies, BispecificGlutamate Carboxypeptidase IIFOLH1 protein, humanProstate-Specific AntigenAntigens, SurfaceCD3 Complex

Autor:innen und Institutionen

  • The Christie NHS Foundation Trust, Manchester, UK.
  • UCLH Foundation Trust, London, UK.
  • Sarah Cannon Research Institute, Nashville, TN, USA.
  • University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.
  • Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Johnson & Johnson, 851 Duportail Road, Chesterbrook, PA, 19087, USA.

Förderung

  • Johnson and Johnson

Zitieren

APA

Hudson, A., Jayaram, A., Garmezy, B., Zorko, N. A., Zarrabi, K. K., Mathews, L., Rupnow, B., Li, M., Ghosh, D., Urtishak, K., Francis, P., Wang, S. C., Attiyeh, E., & de Bono, J. (2026). A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04846-w

Vancouver

Hudson A, Jayaram A, Garmezy B, Zorko NA, Zarrabi KK, Mathews L, et al. A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-025-04846-w

BibTeX
@article{Hudson2026,
  author = {Hudson, Andrew and Jayaram, Anuradha and Garmezy, Benjamin and Zorko, Nicholas A and Zarrabi, Kevin K and Mathews, Ligi and Rupnow, Brent and Li, Mengjie and Ghosh, Debopriya and Urtishak, Karen and Francis, Peter and Wang, Sherry C and Attiyeh, Edward and de Bono, Johann},
  title = {A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  doi = {10.1007/s00280-025-04846-w}
}
Kostenlos starten →